S 12363: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 154572898 |
| MeSH ID | M0176476 |
| Synonym |
|---|
| s-12363 |
| vinfosiltine sulfate |
| s 12363 |
| unii-jt6020n64h |
| vincaleukoblastine, o4-deacetyl-3-de(methoxycarbonyl)-3-(((1-(diethoxyphosphinyl)-2-methylpropyl)amino)carbonyl)-, (3(s))-, sulfate (1:1) (salt) |
| jt6020n64h , |
| 142102-11-2 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Plasma levels of I declined in a triphasic manner with a terminal half-life of approximately 50 h; most drug elimination (55%) being associated with the terminal phase." | ( Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative. Ardiet, C; Clavel, M; Ings, RM; Lelièvre, E; Leyvraz, S; Lokiec, F; Lucas, C; Minaidis, D; Solere, P; Turpin, F, 1992) | 0.28 |
| " Its plasma profile and pharmacokinetic parameters are close to those of other Vinca alkaloids with clearance and terminal half-life being intermediate between those of vinblastine and vincristine." | ( Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. Bourguignat, A; Cardona, H; Guillaudeux, J; Lelievre, E; Lokiec, F; Lucas, C; Sauveur, C; Solere, P, 1993) | 0.29 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " We have evaluated the antitumor activity of a new highly potent vinca-alkaloid derivative, S 12363, in comparison with the activity of the reference compound vinblastine (VLB), when used alone or in combination with verapamil (VRP)." | ( Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft. Arvelo, F; Berlion, M; Bizzari, JP; Bourgeois, Y; Leonce, S; Poupon, MF; Rigaudy, P, ) | 0.13 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " On the in vivo panel of tumors used in this study, S 12363 was at least as active as reference compounds, while its optimal dosage was 10- to 40-fold lower than that of vinblastine, depending on the models studied." | ( Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363. Atassi, G; Berlion, M; Bizzari, JP; Cros, S; Kraus-Berthier, L; Lavielle, G; Pierré, A; Poupon, MF, 1991) | 0.28 |
| " For all cell lines investigated there were similar dose-response curves following two types of S12363 exposure: a single day exposure or three successive daily exposures, the total C x T values being the same in both experimental situations." | ( Evaluation of the time-schedule dependency for the cytotoxic activity of the new vinca alkaloid derivative, S 12363 (vinfosiltine). Berlion, M; Bizzari, JP; Fischel, JL; Formento, P; Milano, G, 1993) | 0.29 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (92.31) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (22.22%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (72.22%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||